BERLIN – Eckert & Ziegler SE (ISIN DE0005659700) announced that its Annual General Meeting held on June 24, 2026, approved a dividend of EUR 0.22 per share for the 2025 fiscal year, up from EUR 0.17 in the previous year. The meeting, conducted in person near the company's headquarters in Berlin, saw representation of 55.37% of the company's share capital. Shareholders endorsed the actions of the Executive Board and Supervisory Board for the 2025 fiscal year and approved all agenda items by a large majority.
The increased dividend signals the company's solid financial health and commitment to shareholder returns. Eckert & Ziegler is a leading specialist in isotope-related components for nuclear medicine and radiation therapy, serving a critical role in the healthcare industry. The company's products and services support early development, contract manufacturing, and distribution for the radiopharmaceutical sector.
With over 1,000 employees, Eckert & Ziegler SE is listed in the TecDAX index of Deutsche Börse. The detailed voting results and the CEO's presentation are available on the company's website at https://www.ezag.com/investors/annual-general-meeting/.
The dividend increase reflects the company's confidence in its ongoing growth and the expanding demand for radiopharmaceutical technologies. As the healthcare industry continues to invest in advanced cancer treatments, Eckert & Ziegler's expertise in nuclear medicine positions it as a key contributor to saving lives. The approved dividend provides a tangible benefit to shareholders, underscoring the company's ability to generate value while advancing medical innovation.
